

First Quarter 2025 Performance Summary

April 2025



TOTAL REVENUE

\$794 M +17% y/y¹



Tyvaso²

\$466M +25% y/y



Remodulin

\$138M +8% y/y



Orenitram

\$121M +14% y/y



Unituxin

\$58M flat y/y



TTM OPERATING
CASH FLOW

\$1.4 billion



CASH, CASH EQUIVALENTS,
& MARKETABLE INVESTMENTS

\$5.0 billion

Quarterly Highlights



**18th consecutive
quarter of y/y
revenue growth**



- Most prescribed U.S. prostacyclin
- Record patient shipments
- Highest revenue quarter



- Most prescribed parenteral prostacyclin in the U.S.
- Record patients on therapy




- Thirteenth sequential quarter of quarterly y/y revenue growth
- Highest revenue quarter



- The most prescribed antibody therapy for high-risk neuroblastoma in the U.S.

Quarterly Revenue, millions USD



NASDAQ

UTHR

2024 Financials

PRODUCT REVENUE

~\$2.9 billion

REVENUE/EMPLOYEE

~\$2.2 million

FOUNDED

1996

HQ

**Research Triangle Park, NC
Silver Spring, MD**

EMPLOYEES

>1,300⁴

1. y/y = year over year. 2. Tyvaso DPI + nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 1Q/20 to 1Q/25. 4. As of 12/31/2024

Pipeline

Development Engine Addressing Unmet Needs

Non-Registration Registration Filed Approved

Tyvaso

TETON 1 - Idiopathic Pulmonary Fibrosis - U.S. and Canada

TETON 2 - Idiopathic Pulmonary Fibrosis - ROW¹

TETON PPF - Progressive Pulmonary Fibrosis

Ralinepag

ADVANCE OUTCOMES - PAH²

Xeno, Organs, and Organ Alternatives

EVLP³/CLES⁴ - Lung Transplant

EXPAND - UKidney™ for End Stage Renal Disease⁵

miroliverELAP⁶ - Acute Liver Failure

Pre-clinical Xeno and Organ Alternative Programs

UThymoKidney™

UHeart™

ULung™

miroliver®

ULobe™

IVIVA Kidney

mirokidney®

Pipeline Spotlights

TETON 1&2
FULLY ENROLLED

**Data Expected
1H26 & 2H25**


EXPAND UKIDNEY™ STUDY

**First Transplant
Expected Mid-25**

EXTEND UTHYMOKIDNEY™
EXPRESS UHEART™

**INDs⁷
Forthcoming**

Positioned for Multiple Waves of Growth⁸



This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. ROW = rest of world outside the U.S. and Canada. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion. 4. CLES = centralized lung evaluation system. 5. Registrational status pending agreement with the FDA. 6. ELAP = external liver assist product. 7. IND = investigational new drug application. 8. Illustrative purposes only

Learn More



United Therapeutics'
Corporate Website



United Therapeutics'
Investor Relations Website



United Therapeutics'
LinkedIn



United Therapeutics'
Corporate Responsibility
Website

